Lipoprotein metabolism and CKD: overview
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Patients with chronic kidney disease (CKD) frequently display abnormalities of plasma lipids and lipoproteins. These abnormalities include hypertriglyceridemia associated with elevated levels of very low-density lipoproteins (VLDLs) and chylomicrons. There is often also an increase in the concentration of the atherogenic, cholesterol-enriched remnants of VLDLs and chylomicrons. The concentration of low-density lipoprotein cholesterol is usually normal, but there is frequently a decrease in concentration of the cardio-protective high-density lipoproteins. There is also often an increase in the concentration of the atherogenic lipoprotein (a) particles. This article provides an overview of plasma lipoprotein transport and identifies mechanisms responsible for the abnormalities observed in patients with CKD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with CKD, especially those under hemodialysis, do not usually have high levels of LDL-C, but increased TG and decreased HDL-C levels [87].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [87]
Citations
Cites
Antiinflammatory Properties of HDL
Barter, P. J., Nicholls, S., Rye, K.-A., Anantharamaiah, G. M., Navab, M., & Fogelman, A. M. (2004) · Circulation Research · doi:10.1161/01.res.0000146094.59640.13 · Cited by 1,394 · cited 1×
“HDLs have a number of functions that have the potential to protect against atherosclerotic cardiovascular disease [10].”
BackgroundSelf-citationLipoprotein Metabolism and Renal Failure
Attman, P.-O., Samuelsson, O., & Alaupovic, P. (1993) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80030-8 · Cited by 355 · cited 1×
“There is frequently a decreased concentration of high-density lipoprotein (HDL) cholesterol [5–7].”
BackgroundLipoprotein metabolism and lipid management in chronic kidney disease
Kwan, B. C. H., Kronenberg, F., Beddhu, S., & Cheung, A. K. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006091006 · Cited by 354 · cited 1×
“These include elevated levels of very low-density lipoproteins (VLDLs) and chylomicrons resulting in an increased concentration of plasma triglyceride [1, 2].”
BackgroundEffects of High-Density Lipoproteins on Pancreatic β-Cell Insulin Secretion
Fryirs, M. A., Barter, P. J., Appavoo, M., Tuch, B. E., Tabet, F., Heather, A. K., & Rye, K.-A. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207373 · Cited by 286 · cited 1×
“They enhance endothelial function, promote endothelial repair, increase angiogenesis, suppress the production and mobilization of monocytes and neutrophils from bone marrow and have recently been reported to have antidiabetic properties [11].”
BackgroundSelf-citationSelective Deficiency of Hepatic Triglyceride Lipase in Uremic Patients
Mordasini, R., Frey, F., Flury, W., Klose, G., & Greten, H. (1977) · New England Journal of Medicine · doi:10.1056/nejm197712222972502 · Cited by 172 · cited 1×
“An increase in levels of the remnants of VLDLs and chylomicrons is most likely the result of a reduced activity of HL [14], an enzyme responsible for the catabolism of TRL remnants.”
BackgroundVaziri, N. D., Liang, K., & Parks, J. S. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00734.x · Cited by 147 · cited 1×
“with impaired renal function frequently have diminished activity of LCAT [15, 16] and also an increased activity of CETP [17], both of which will contribute to a reduced level of HDL cholesterol (Fig.”
BackgroundDeighan, C. J., CASLAKE, M. J., McConnell, M., Boulton‐Jones, J. M., & Packard, C. J. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70255-1 · Cited by 140 · cited 1×
“The concentration of low-density lipoprotein (LDL) cholesterol is usually normal, although the LDL particles may be smaller and denser than normal [3, 4].”
BackgroundNobécourt, E., Davies, M. J., Brown, B. E., Curtiss, L. K., Bonnet, D. J., Charlton, F., Januszewski, A. S., Jenkins, A. J., Barter, P. J., & Rye, K. (2007) · Diabetologia · doi:10.1007/s00125-006-0574-z · Cited by 138
Self-citationDown-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure
Vaziri, N. D., & Liang, K. (1996) · Kidney International · doi:10.1038/ki.1996.515 · Cited by 118 · cited 1×
“The main mechanism responsible for the increased concentration of TRLs in patients with CKD is a delayed catabolism of the triglyceride in VLDLs and chylomicrons, secondary to a diminished activity of LPL resulting from both downregulation of the enzyme gene and the presence of lipase inhibitors in plasma [12, 13].”
BackgroundHepatic HDL receptor, SR-B1 and Apo A-I expression renal failure
Vaziri, N. D., Deng, G., & Liang, K. (1999) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/14.6.1462 · Cited by 113 · cited 1×
“There is frequently a decreased concentration of high-density lipoprotein (HDL) cholesterol [5–7].”
Background
Cited by
The effects of exercise training on lipid metabolism and coronary heart disease
Muscella, A., Stefàno, E., & Marsigliante, S. (2020) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00708.2019 · Cited by 238
The Regulation of Fat Metabolism during Aerobic Exercise
Muscella, A., Stefàno, E., Lunetti, P., Capobianco, L., & Marsigliante, S. (2020) · Biomolecules · doi:10.3390/biom10121699 · Cited by 237
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0823-5 · Cited by 191
Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins
Florens, N., Calzada, C., Lyasko, E., Juillard, L., & Soulage, C. O. (2016) · Toxins · doi:10.3390/toxins8120376 · Cited by 140
“CKD is associated with dyslipidemia associating hypertriglyceridemia, elevated LDL cholesterol, an accumulation of ApoB containing lipoproteins, increased concentrations of lipoprotein(a) particles and low HDL levels [14,15].”
BackgroundRole of Myeloperoxidase in Patients with Chronic Kidney Disease
Kisic, B., Miric, D., Dragojevic, I., Rasic, J., & Popovic, L. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/1069743 · Cited by 100
“oxidativemodification and carbamylation of apolipoproteins, downregulation of gene encoding lipoprotein lipase, and many others [60].”
Background
Metadata
- Authors
- Barter, P.
- Affiliations
- UNSW Sydney (AU)
- Corresponding author
- Barter, Philip
- Venue
- Clinical and Experimental Nephrology
- Published
- 2013-09-20
- Volume
- 18
- Issue
- 2
- Pages
- 243-246
- ISSN
- 1342-1751 (ISSN-L)
- 1437-7799
- OpenAlex
- W2028284386
- Cited by
- 42
- References
- 20
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 4 · 2022: 7 · 2021: 2 · 2020: 10 · 2019: 4 · 2018: 4 · 2017: 3 · 2016: 2 · 2014: 1
- FWCI
- 0.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Clinical and Experimental Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- chronic kidney disease, lipoprotein metabolism, dyslipidemia, hypertriglyceridemia, VLDL, chylomicrons, remnant lipoproteins, LDL cholesterol, high-density lipoprotein, lipoprotein(a), atherosclerosis
- MeSH terms
- Chylomicrons, Humans, Lipoproteins, Lipoproteins, HDL, Lipoproteins, LDL, Lipoproteins, VLDL, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipoprotein metabolism and CKD: overview. https://app.cochat.ai/papers/10.1007/s10157-013-0866-9
- The paper
- Barter, P. (2014). Lipoprotein metabolism and CKD: overview. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-013-0866-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.